on January 25, 2012 |
Permalink |
Comments (0)
Topics: Surgery, Service Lines
Charlotte Tsui
Last month, just two weeks shy of Christmas, Intuitive Surgical announced the FDA approval of its much buzzed-about single-site port device. The approval, which was limited to cholecystectomy procedures, is a noteworthy development given that it involves a potentially less invasive approach to what is already considered to be one of the most minimally invasive approaches to surgery.
Here are our key takeaways from this approval:
1. The approval is limited to cholecystectomy, a routine general surgery procedure for which laparoscopy remains the overwhelming standard of care. Based on published literature, the da Vinci offers little incremental value over laparoscopy for cholecystectomy.
Given the prodigious costs of the robot, using the da Vinci for a straightforward case like cholecystectomy is often seen as unnecessary and somewhat excessive. Cholecystectomy falls under the purview of general surgeons, a group that remains skeptical of the robot and the clinical benefits it affords over standard approaches for procedures of the abdomen.
While the potential for robotics is arguably promising for subspecialties like colorectal surgery—there is greater incremental opportunity to be had for increased dexterity afforded by the da Vinci in the tight, hard-to-navigate regions of the lower GI anatomy—the case for using the da Vinci for simpler abdominal procedures (i.e. cholecystectomy, appendectomy) is weak.
2. Single incision surgery by itself, without the robot, is not yet widely embraced. In fact, many still argue that single incision surgery has little clinical merit over traditional multi-port laparoscopy. It is too early to tell what impact the robotics will have on single-site laparoscopy, although it seems that the marriage of the two historically contentious modalities spurs more questions than answers.
As it stands, there are only a handful of articles on the topic, and of these, most are feasibility studies. The few available discussions in literature pose both pros (i.e. easier maneuverability) and cons (i.e. robotic hardware and software is not made for single site surgery), but these do not stack up clearly in favor of one side or the other.
The bottom line: the market’s reaction to the new Single-Site port for cholecystectomy is likely to be cautious. Although this clearance may open doors for other robotic single-site applications down the line, its clinical value is uncertain relative to the widely accepted standard of laparoscopic cholecystectomy. The lesser degree of da Vinci adoption by general surgeons relative to other specialists, as well as the competition presented by conventional laparascopic means for these cases, presents additional hurdles for robotic single-site cholecystectomy.
